The majority of patients who undergo transcatheter aortic valve replacement (TAVR) have hypertension that requires pharmacotherapeutic intervention. Unlike ischemic heart disease, especially in patients with reduced ejection fraction where the use of renin-angiotensin inhibitors (RAI) is associated with improved cardiovascular outcomes, there is little guidance or consensus regarding the therapeutic choice for post-procedural management of patients after (TAVR) except for antithrombotics. Post-TAVR antihypertensive management usually follows the standard recommendations for essential hypertension. However, data are emerging for the support of the use of RAI as a primary agent after TAVR. Accordingly, the purpose of this study was to perform a meta-analysis of all the studies that have reported cardiovascular outcomes with the use of RAI compared to no RAI in patients after TAVR.